Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
(1) Background: BRAFi/MEKi are usually offered as a first line treatment for patients requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor burden, and with brain metastases. The efficacy of second line therapies after BRAFi/MEKI failure is now well defined. (2) M...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/9/2123 |
| _version_ | 1797505387972263936 |
|---|---|
| author | Paweł Rogala Anna M. Czarnecka Bożena Cybulska-Stopa Krzysztof Ostaszewski Karolina Piejko Marcin Ziętek Robert Dziura Ewa Rutkowska Łukasz Galus Natasza Kempa-Kamińska Joanna Seredyńska Wiesław Bal Katarzyna Kozak Anna Surus-Hyla Tomasz Kubiatowski Grażyna Kamińska-Winciorek Rafał Suwiński Jacek Mackiewicz Piotr Rutkowski |
| author_facet | Paweł Rogala Anna M. Czarnecka Bożena Cybulska-Stopa Krzysztof Ostaszewski Karolina Piejko Marcin Ziętek Robert Dziura Ewa Rutkowska Łukasz Galus Natasza Kempa-Kamińska Joanna Seredyńska Wiesław Bal Katarzyna Kozak Anna Surus-Hyla Tomasz Kubiatowski Grażyna Kamińska-Winciorek Rafał Suwiński Jacek Mackiewicz Piotr Rutkowski |
| author_sort | Paweł Rogala |
| collection | DOAJ |
| description | (1) Background: BRAFi/MEKi are usually offered as a first line treatment for patients requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor burden, and with brain metastases. The efficacy of second line therapies after BRAFi/MEKI failure is now well defined. (2) Methods: Patients treated with first line target BRAFi/MEKi therapy (vemurafenib plus cobimetinib, dabrafenib plus trametinib or encorafenib plus binimetinib); and for the second line treatment immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab or pembrolizumab) with at least one cycle of second line were analyzed for survival and prognostic biomarkers. (3) Results: There were no statistically significant differences in ORR between the treatment groups with nivolumab and pembrolizumab, as well as median progression free-survival (PSF) and overall survival (OS) since the initiation of second line therapy; on nivolumab OS was 6.6 months, and on pembrolizumab 5.0 months. The greatest clinical benefit with second line immunotherapy was observed in patients with LDH ≤ ULN and <3 organ sites with metastasis at baseline. Longer OS was also noted in patients with time to PD >6 months in first line (slow progression). (4) Conclusions: Second line anti-PD1 immunotherapy is effective in BRAF-mutated melanoma patients after BRAFi/MEKi therapy failure. |
| first_indexed | 2024-03-10T04:18:52Z |
| format | Article |
| id | doaj.art-4ef8d0c5ad5b4202b44452570df2abb0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:18:52Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4ef8d0c5ad5b4202b44452570df2abb02023-11-23T07:55:12ZengMDPI AGCancers2072-66942022-04-01149212310.3390/cancers14092123Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma PatientsPaweł Rogala0Anna M. Czarnecka1Bożena Cybulska-Stopa2Krzysztof Ostaszewski3Karolina Piejko4Marcin Ziętek5Robert Dziura6Ewa Rutkowska7Łukasz Galus8Natasza Kempa-Kamińska9Joanna Seredyńska10Wiesław Bal11Katarzyna Kozak12Anna Surus-Hyla13Tomasz Kubiatowski14Grażyna Kamińska-Winciorek15Rafał Suwiński16Jacek Mackiewicz17Piotr Rutkowski18Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, 31-115 Kraków, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, 31-115 Kraków, PolandDepartment of Surgical Oncology, Wroclaw Comprehensive Cancer Center, 53-413 Wroclaw, PolandDepartment of Clinical Oncology, Holy Cross Cancer Center, 25-734 Kielce, PolandDepartment of Clinical Oncology, Holy Cross Cancer Center, 25-734 Kielce, PolandDepartment of Medical and Experimental Oncology, University of Medical Sciences, 61-701 Poznan, PolandDepartment of Clinical Oncology, Wroclaw Comprehensive Cancer Center, 53-413 Wroclaw, PolandDepartment of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, 31-115 Kraków, PolandDepartment of Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandClinical Department of Oncology and Immuno-Oncology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, 10-228 Olsztyn, PolandClinical Department of Oncology and Immuno-Oncology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, 10-228 Olsztyn, PolandThe Skin Cancer and Melanoma Team, Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, PolandII Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, PolandDepartment of Medical and Experimental Oncology, University of Medical Sciences, 61-701 Poznan, PolandDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland(1) Background: BRAFi/MEKi are usually offered as a first line treatment for patients requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor burden, and with brain metastases. The efficacy of second line therapies after BRAFi/MEKI failure is now well defined. (2) Methods: Patients treated with first line target BRAFi/MEKi therapy (vemurafenib plus cobimetinib, dabrafenib plus trametinib or encorafenib plus binimetinib); and for the second line treatment immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors (nivolumab or pembrolizumab) with at least one cycle of second line were analyzed for survival and prognostic biomarkers. (3) Results: There were no statistically significant differences in ORR between the treatment groups with nivolumab and pembrolizumab, as well as median progression free-survival (PSF) and overall survival (OS) since the initiation of second line therapy; on nivolumab OS was 6.6 months, and on pembrolizumab 5.0 months. The greatest clinical benefit with second line immunotherapy was observed in patients with LDH ≤ ULN and <3 organ sites with metastasis at baseline. Longer OS was also noted in patients with time to PD >6 months in first line (slow progression). (4) Conclusions: Second line anti-PD1 immunotherapy is effective in BRAF-mutated melanoma patients after BRAFi/MEKi therapy failure.https://www.mdpi.com/2072-6694/14/9/2123melanomaimmunotherapynivolumabpembrolizumabBRAF |
| spellingShingle | Paweł Rogala Anna M. Czarnecka Bożena Cybulska-Stopa Krzysztof Ostaszewski Karolina Piejko Marcin Ziętek Robert Dziura Ewa Rutkowska Łukasz Galus Natasza Kempa-Kamińska Joanna Seredyńska Wiesław Bal Katarzyna Kozak Anna Surus-Hyla Tomasz Kubiatowski Grażyna Kamińska-Winciorek Rafał Suwiński Jacek Mackiewicz Piotr Rutkowski Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients Cancers melanoma immunotherapy nivolumab pembrolizumab BRAF |
| title | Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients |
| title_full | Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients |
| title_fullStr | Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients |
| title_full_unstemmed | Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients |
| title_short | Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients |
| title_sort | long term results and prognostic biomarkers for anti pd1 immunotherapy used after brafi meki combination in advanced cutaneous melanoma patients |
| topic | melanoma immunotherapy nivolumab pembrolizumab BRAF |
| url | https://www.mdpi.com/2072-6694/14/9/2123 |
| work_keys_str_mv | AT pawełrogala longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT annamczarnecka longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT bozenacybulskastopa longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT krzysztofostaszewski longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT karolinapiejko longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT marcinzietek longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT robertdziura longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT ewarutkowska longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT łukaszgalus longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT nataszakempakaminska longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT joannaseredynska longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT wiesławbal longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT katarzynakozak longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT annasurushyla longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT tomaszkubiatowski longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT grazynakaminskawinciorek longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT rafałsuwinski longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT jacekmackiewicz longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients AT piotrrutkowski longtermresultsandprognosticbiomarkersforantipd1immunotherapyusedafterbrafimekicombinationinadvancedcutaneousmelanomapatients |